The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
Pivotal data set the stage for slightly delayed US accelerated approval filing.
But results come from a curated dataset, with no in-trial comparator.
The latest projects newly into human trials include BNT3212.
Global data are in the same ballpark as Chinese results presented earlier this year.
A common mutation comes into play for PRMT5 inhibition.
